|
| 36912782 | Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners. | Mol Cancer Ther | 2023 |
| 35929986 | Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. | Clin Cancer Res | 2022 |
| 32692162 | Challenges and Opportunities in Cancer Drug Resistance. | Chem Rev | 2021 |
| 33718951 | How a new drug is born. | Eur Heart J | 2021 |
| 33785652 | Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. | Mol Cancer Ther | 2021 |
| 33495510 | Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy. | Commun Biol | 2021 |
| 34570508 | Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. | J Med Chem | 2021 |
| 33273059 | AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. | Mol Cancer Ther | 2021 |
| 33259592 | Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. | Blood | 2021 |
| 32297743 | Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. | J Med Chem | 2020 |
| 31786184 | EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. | Cell Chem Biol | 2020 |
| 31699827 | AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. | Clin Cancer Res | 2020 |
| 32717371 | Optimization of a series of potent, selective and orally bioavailable SYK inhibitors. | Bioorg Med Chem Lett | 2020 |
| 32943458 | <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1. | Clin Cancer Res | 2020 |
| 32910656 | Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. | J Med Chem | 2020 |
| 32627965 | Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. | Mol Syst Biol | 2020 |
| 32988967 | AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. | Clin Cancer Res | 2020 |
| 32727810 | Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunity. | J Immunother Cancer | 2020 |
| 32350132 | Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. | Sci Transl Med | 2020 |
| 31209238 | Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. | Nat Commun | 2019 |
| 31699977 | AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. | Nat Commun | 2019 |
| 29533782 | BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. | Cancer Cell | 2018 |
| 30036377 | BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. | PLoS One | 2018 |
| 30297535 | Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. | Cancer Res | 2018 |
| 30335946 | Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. | ACS Chem Biol | 2018 |
| 29636547 | BRD4 facilitates replication stress-induced DNA damage response. | Oncogene | 2018 |
| 29245897 | Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum. | Oncotarget | 2017 |
| 26832798 | Dissecting Therapeutic Resistance to ERK Inhibition. | Mol Cancer Ther | 2016 |
| 27472462 | Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. | Oncotarget | 2016 |
| 27573426 | AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. | Mol Cancer Ther | 2016 |
| 25537515 | Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. | Oncotarget | 2015 |
| 25779944 | The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models. | Clin Cancer Res | 2015 |
| 25104330 | Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. | Cancer Discov | 2014 |
| 25289887 | MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. | PLoS One | 2014 |
| 23699655 | Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. | Mol Cancer Ther | 2013 |
| 23614898 | Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. | Cancer Discov | 2013 |
| 23323157 | Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. | Transl Oncol | 2012 |
| 20127862 | Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. | Int J Cancer | 2010 |
| 20713706 | Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. | Proc Natl Acad Sci U S A | 2010 |
| 19759537 | Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. | Nature | 2009 |
| 18199553 | Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. | Cancer Res | 2008 |
| 18089776 | A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. | Cancer Res | 2007 |
| 17018619 | Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. | Cancer Res | 2006 |
| 16288033 | Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. | Cancer Res | 2005 |
| 11162308 | Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. | Mol Ther | 2001 |
| 11435460 | Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. | J Clin Invest | 2001 |
| 9826714 | Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. | Proc Natl Acad Sci U S A | 1998 |
| 9395478 | Fibronectin type III repeats mediate RGD-independent adhesion and signaling through activated beta1 integrins. | J Biol Chem | 1997 |
| 8647938 | The alpha1beta1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. | J Clin Invest | 1996 |
| 8970166 | Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. | Mol Biotechnol | 1996 |